Kineta, Inc., a biotechnology company, engages in the discovery and development of antiviral therapies and immune modulating drugs for the treatment of RNA viruses that include hepatitis C, influenza, west nile virus, and common cold. It offers ShK Analogs for treatment of multiple sclerosis and autoimmune diseases; and RIG-I Pathway, a molecular on/off switch that triggers the human body's immune defenses against virus infection. Kineta, Inc. was formerly known as Lecura, Inc. The company was founded in 2007 and is based in Seattle, Washington.
Current Team (4)Update
Funding Rounds (6) - $9.8MUpdate
219 Terry Ave N
Seattle, WA 98109-5208